HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Fosfomycin
FOM · fosfocina · PHOSPHOMYCIN · fosfonomycin · 883a · mk-955 · C06454 · MK 0955
Identifikatoren & physikalische Daten
| CAS No. | 23155-02-4 |
|---|---|
| Summenformel | C3H7O4P |
| Durchschnittliche Molmasse | 138,06 g/mol |
| Monoisotopische Masse | 138,0081957 g/mol |
| SMILES | C[C@@H]1O[C@@H]1P(=O)(O)O |
| InChIKey | YMDXZJFXQJVXBF-STHAYSLISA-N |
| PubChem CID | 446987 |
| ChEMBL | CHEMBL1757 |
| ChEBI | CHEBI:28915 |
| EC No. | 245-463-1 |
| DTXSID | DTXSID4048480 |
| Lokaler Name | Fosfomycin |
Chemische & physikalische Eigenschaften
| XLogP | -1,4 |
|---|---|
| Polarare Oberfläche (TPSA) | 70,1 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 8 |
| Formalladung | 0 |
| Komplexität | 138 |
| Arzneimittel | Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland |
| LogP (Verteilungskoeffizient) | -1.6 |
| Löslichkeit | 4.69e+01 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanAntibacterial AgentsAnti-Infective Agents, Urinary |
| Schmelzpunkt | 94 °C94°C |
| Physical Description | Solid |
| Siedepunkt | 342.7±52.0 °C(Predicted) |
| Dichte | 1.56±0.1 g/cm3(Predicted) |
| pKa (Säurekonstante) | 3.20±0.40(Predicted) |
| Aggregatzustand | solid |
| CAS Datenbank | 23155-02-4(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 100% (4 of 4) of all reports.Not ClassifiedAggregated GHS information provided per 4 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Fosfomycin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| Hazard Classes and Categories | Not Classified |
| Hepatotoxicity | Serum aminotransferase elevations occur in a small proportion of patients after a single oral dose of fosfomycin (1-2%), but at rates similar to those with comparator antibiotics. Nevertheless, serum enzyme elevations are mentioned as potential adverse events in the product label for fosfomycin. In addition, a small number of cases of clinically apparent liver injury attributed to fosfomycin have been published. The time to onset has been short, within one week of a single oral dose or within the first week of intravenous therapy, and the pattern of liver enzyme elevations has been mixed or hepatocellular. The injury has typically been mild and self-limited, and no cases of fatal acute liver failure, chronic hepatitis or vanishing bile duct syndrome have been convincingly linked to fosfomycin. The number of cases described has been too few to establish a typical clinical pattern, but immunoallergic features and autoimmune markers appear to be uncommon. |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)fosfomycinDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| EPA Human Health Benchmarks for Pharmaceuticals | Fosfomycin69.9295.9The recommended dosage for women 18 years of age and older for uncomplicated urinary tract infection (acute cystitis) is one sachet (3 g of fosfomycin).Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 3000 mg/day, Lowest Therapeutic Dose (LTD): 37.5 mg/kg-day, and Screening Dose: 0.01 mg/kg-day. |
Anwendungen & Verwendung
Verwenden
Antibacterial.